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ABSTRACT CD137, a member of the tumor necrosis factor receptor superfamily of
cell surface proteins, acts as a costimulatory receptor on T cells, natural killer cells, B
cell subsets, and some dendritic cells. Agonistic anti-CD137 monoclonal antibody
(MAb) therapy has been combined with other chemotherapeutic agents in human
cancer trials. Based on its ability to promote tumor clearance, we hypothesized that
anti-CD137 MAb might activate immune responses and resolve chronic viral infections. We evaluated anti-CD137 MAb therapy in a mouse infection model of chikungunya virus (CHIKV), an alphavirus that causes chronic polyarthritis in humans and is
associated with reservoirs of CHIKV RNA that are not cleared efﬁciently by adaptive
immune responses. Analysis of viral tropism revealed that CHIKV RNA was present
preferentially in splenic B cells and follicular dendritic cells during the persistent
phase of infection, and animals lacking B cells did not develop persistent CHIKV infection in lymphoid tissue. Anti-CD137 MAb treatment resulted in T cell-dependent
clearance of CHIKV RNA in lymphoid tissue, although this effect was not observed in
musculoskeletal tissue. The clearance of CHIKV RNA from lymphoid tissue by antiCD137 MAb was associated with reductions in the numbers of germinal center B
cells and follicular dendritic cells. Similar results were observed with anti-CD137 MAb
treatment of mice infected with Mayaro virus, a related arthritogenic alphavirus.
Thus, anti-CD137 MAb treatment promotes resolution of chronic alphavirus infection
in lymphoid tissues by reducing the numbers of target cells for infection and persistence.
IMPORTANCE Although CHIKV causes persistent infection in lymphoid and musculo-

skeletal tissues in multiple animals, the basis for this is poorly understood, which has
hampered pharmacological efforts to promote viral clearance. Here, we evaluated
the therapeutic effects on persistent CHIKV infection of an agonistic anti-CD137 MAb
that can activate T cell and natural killer cell responses to clear tumors. We show
that treatment with anti-CD137 MAb promotes the clearance of persistent alphavirus RNA from lymphoid but not musculoskeletal tissues. This occurs because
anti-CD137 MAb-triggered T cells reduce the numbers of target germinal center
B cells and follicular dendritic cells, which are the primary reservoirs for CHIKV in
the spleen and lymph nodes. Our studies help to elucidate the basis for CHIKV
persistence and begin to provide strategies that can clear long-term cellular reservoirs of infection.
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argeting of CD137 with an agonistic monoclonal antibody (MAb) enhances the
spontaneous and antibody (Ab)-dependent cell-mediated cytotoxicity of natural
killer (NK) cells and the proliferation and survival of CD8⫹ T cells. Anti-CD137 MAb also
enhances antigen presentation by promoting costimulatory activity of dendritic cells
(DCs) and by inhibiting the functions of regulatory T cells (1). Based on preclinical
studies demonstrating anti-CD137 MAb as a promising cancer immunotherapy (2–6),
human clinical trials that combine anti-CD137 MAb with conventional chemotherapies
for the treatment of metastatic solid tumors, non-small-cell lung cancer, melanoma,
non-Hodgkin’s B cell lymphoma, colorectal cancer, and multiple myeloma have been
initiated (1).
Chikungunya virus (CHIKV) is a reemerging alphavirus of the Togaviridae family that
is transmitted by Aedes species mosquitoes. CHIKV was ﬁrst isolated in Tanzania in 1952
and has historically caused infections in Africa and Asia (7). In 2013, CHIKV spread into
South and Central America, and an epidemic caused over 1.8 million infections,
including cases in the United States (8). Infected individuals present with fever, rash,
malaise, myalgia, and polyarthritis (9). Although symptoms can resolve within a few
weeks, 30% to 60% of individuals report persistent musculoskeletal pain months to
years after initial diagnosis (10–12). Indeed, CHIKV RNA and protein have been detected
in perivascular synovial macrophages 18 months after infection (13). Persistent viral
RNA in cells may act as a pathogen-associated molecular pattern (PAMP) and contribute
to CHIKV-induced inﬂammation and arthritis (14–16).
In murine models of CHIKV, infectious virus is cleared from the blood and most
tissues by 7 days postinfection (dpi). However, CHIKV RNA can be detected in musculoskeletal tissues, the spleen, and lymph nodes of immunocompetent mice for months
(17). Although combinations of anti-CHIKV MAb with CTLA4-Ig, an immunomodulatory
drug, controlled CHIKV arthritis in mice (18), antiviral antibody, alone or in combination
with CTLA4-Ig, did not clear CHIKV RNA from sites of persistence when administered
after infection. Based on studies in cancer models, we hypothesized that an agonistic
anti-CD137 MAb could activate immune responses to resolve chronic viral infections.
Here, we evaluated the activity of anti-CD137 MAb in a model of CHIKV arthritis in
immunocompetent C57BL/6 mice. Treatment with an agonistic anti-CD137 MAb promoted clearance of persistent CHIKV RNA in the spleen and the draining lymph node
(DLN), and this effect required the presence of T cells. However, clearance was not
observed in musculoskeletal tissues. Viral RNA tropism studies revealed that B cells and
follicular dendritic cells (FDCs) harbored much of the CHIKV RNA in lymphoid tissues.
Unexpectedly, anti-CD137 MAb treatment resulted in reduced numbers of germinal
center B cells and FDCs, compared with isotype-control MAb-treated animals. Thus,
anti-CD137 MAb treatment cleared viral RNA in the spleen through either direct killing
or indirect effects by T cells. As similar results were seen in mice with a second
emerging alphavirus, Mayaro virus (MAYV), anti-CD137 MAb treatment resolves chronic
alphavirus infection in lymphoid tissues by reducing the numbers of germinal center B
cells and FDCs, which are the primary viral reservoirs in these tissues.
RESULTS
Anti-CD137 MAb treatment reduces CHIKV RNA levels in lymphoid but not
musculoskeletal tissues. We hypothesized that agonistic anti-CD137 MAb might
stimulate the immune system to clear chronic viral infections, analogous to its ability to
reduce tumor burdens (1). To test this idea, we used a murine model of CHIKV infection.
Four-week-old wild-type (WT) C57BL/6 male mice inoculated subcutaneously with
CHIKV in the foot develop a biphasic pattern of joint swelling, with persistent viral RNA
present in the musculoskeletal tissues of the ipsilateral and contralateral feet, the
spleen, and the DLN (Fig. 1) (17); this viral RNA is maintained although infectious
virus cannot be recovered after 7 dpi in immunocompetent mice (19). CHIKVinfected mice treated therapeutically with agonistic anti-CD137 MAb at 2 dpi
developed increased foot swelling from 7 to 10 dpi, compared with isotype-control
MAb-treated animals (Fig. 1A). Associated with this, we observed increased numDecember 2019 Volume 93 Issue 24 e01231-19
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FIG 1 Anti-CD137 MAb treatment increases foot swelling but reduces viral RNA levels in the spleen and DLN. Four-week-old WT C57BL/6 male mice were
inoculated with 103 FFU of CHIKV-LR at day 0. At 2 dpi, 400 g of agonistic anti-CD137 MAb or isotype-control MAb was administered via the i.p. route. (A) Foot
swelling was measured with digital calipers (15 to 18 mice per group). Each symbol represents the mean value for a group, and bars indicate standard
deviations. **, P ⬍ 0.01; ****, P ⬍ 0.0001, two-way ANOVA with Šidák’s posttest. (B) Ipsilateral feet were harvested at 7 dpi and processed for ﬂow cytometry to
quantify immune cell inﬁltrates. (C to G) The experimental scheme (C) shows that ipsilateral (D) and contralateral (E) feet, spleen (F), and DLN (G) were harvested
at 7, 14, and 28 dpi. Viral RNA from tissue homogenates was measured by qRT-PCR. (H to L) The experimental scheme (H) shows that 400 g of agonistic
anti-CD137 MAb or isotype-control MAb was administered i.p. at the same time as virus inoculation, and ipsilateral (I) and contralateral (J) feet, spleen (K), and
DLN (L) were harvested at 14 dpi. Viral RNA from tissue homogenates was measured by qRT-PCR. (M) Four-week-old CD137⫺/⫺ C57BL/6 mice were inoculated
with 103 FFU of CHIKV-LR at day 0. At 2 dpi, 400 g of agonistic anti-CD137 MAb or isotype-control MAb was administered via the i.p. route. Spleens were
harvested at 14 dpi, and viral RNA from tissue homogenates was measured by qRT-PCR. Each symbol represents an individual mouse, and bars indicate median
values. Data in panels B, D to G, and I to M were pooled from two or three experiments. *, P ⬍ 0.05; **, P ⬍ 0.01; ****, P ⬍ 0.0001; n.s., not signiﬁcant,
Mann-Whitney test.
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bers of CD8⫹ T cells (3.3-fold; P ⬍ 0.01) and Ly6G⫹ neutrophils (3.0-fold; P ⬍ 0.01)
in the joints of anti-CD137 MAb-treated mice, compared with isotype-control
MAb-treated animals, at 7 dpi (Fig. 1B).
Despite the changes in foot swelling induced by anti-CD137 MAb treatment, no
differences in viral RNA levels were observed in the ipsilateral or contralateral foot at 7,
14, or 28 dpi (Fig. 1C to E). Similarly, the amount of CHIKV RNA in the ipsilateral or
contralateral foot did not change, compared with isotype-control MAb-treated animals,
at 14 dpi when mice were treated with anti-CD137 MAb at day 0, at the same time as
virus inoculation (Fig. 1H to J).
Although anti-CD137 MAb treatment at 0 or 2 dpi failed to clear CHIKV RNA in
musculoskeletal tissues, we observed reduced viral RNA levels in the spleen at 7 dpi,
compared with isotype-control MAb treatment (Fig. 1F). At 14 and 28 dpi, anti-CD137
MAb-treated mice showed greater reductions in CHIKV RNA levels in the spleen (⬃130to 220-fold; P ⬍ 0.0001) than isotype-control MAb-treated animals. In most animals (7
of 10 animals) treated with a single dose of anti-CD137 MAb at 2 dpi, viral RNA was not
detected in the spleen at 28 dpi (Fig. 1F). Reduced levels of CHIKV RNA in the DLN
(110-fold; P ⬍ 0.0001) also were observed at 14 dpi after anti-CD137 MAb treatment
(Fig. 1G). At 28 dpi, however, CHIKV RNA in the DLN was absent in most anti-CD137
MAb-treated and isotype-control MAb-treated animals (Fig. 1G). When mice were
treated with anti-CD137 MAb at 0 dpi, the amounts of CHIKV RNA in the spleen and the
DLN at 14 dpi also were substantially reduced (140- to 7,000-fold; P ⬍ 0.05), compared
with isotype-control MAb-treated animals (Fig. 1K and L). We conﬁrmed the speciﬁcity
of the effect; treatment of CHIKV-infected CD137⫺/⫺ mice with agonistic anti-CD137
MAb at 2 dpi did not reduce viral RNA levels in the spleen (Fig. 1M).
Effect of anti-CD137 MAb on CHIKV tropism in the spleen. To begin to elucidate
how anti-CD137 MAb treatment promoted clearance of CHIKV RNA in the spleen, we
explored the cellular tropism of the virus in this tissue, which has remained undeﬁned.
Initially, we performed viral RNA in situ hybridization (ISH) with spleens from CHIKVinfected mice treated with anti-CD137 MAb or isotype-control MAb. At 7 dpi, much of
the viral RNA was present in the center of lymphoid follicles of anti-CD137 MAb- or
isotype-control MAb-treated animals (Fig. 2A and B). To deﬁne the cell types harboring
CHIKV RNA, we sorted splenocyte subsets at 7 and 14 dpi by ﬂow cytometry and
performed quantitative reverse transcription-PCR (qRT-PCR); cells were ﬁxed with paraformaldehyde (PFA) prior to sorting because of containment issues, as infectious CHIKV
is a biosafety level 3 agent. At 7 and 14 dpi, FDCs and germinal center B cells contained
the highest relative levels of CHIKV RNA, on a per-cell basis, in the spleens of isotypecontrol MAb-treated animals (Fig. 2C). When anti-CD137 MAb treatment was administered at 2 dpi, CHIKV RNA was preferentially cleared from FDCs at 7 dpi and was not
appreciably detected in any splenocyte subsets at 14 dpi. During productive CHIKV
infection, the subgenomic mRNA segment encoding the structural proteins (C-E3-E26K-E1) is preferentially transcribed, compared to the genomic RNA (20); this results in
more copies of structural proteins, such as E1, than nonstructural proteins. As a
surrogate assay for detection of infectious virus in the spleen, we measured the ratio of
subgenomic RNA (E1 RNA) to genomic RNA (nsP2 RNA) by qRT-PCR. At least through
14 dpi, the ratio of E1 RNA to nsP2 RNA was greater than 1 (Fig. 2D to F), suggesting
active infection.
In addition to altering CHIKV persistence in the spleen, we speculated that antiCD137 MAb treatment might affect speciﬁc immune cell populations after infection.
Anti-CD137 MAb treatment did not diminish the total number of leukocytes in the
spleen (Fig. 3A), and we even observed a small increase (1.6-fold; P ⬍ 0.01) in the
number of CD3⫹ T cells at 14 dpi (Fig. 3B). However, we did observe a small decrease
(1.4-fold; P ⬍ 0.01) in the number of CD19⫹ B cells (Fig. 3C) and markedly reduced (up
to ⬃40-fold; P ⬍ 0.01) numbers of peanut agglutinin-positive (PNA⫹) CD95⫹ or GL7⫹
CD95⫹ germinal center B cells and CD45⫺ CD54⫹ CD21/CD35⫹ FDCs at 7 and 14 dpi
(Fig. 3D to G). To test whether inhibition of germinal center development affected
December 2019 Volume 93 Issue 24 e01231-19
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FIG 2 Germinal center (GC) B cells and FDCs harbor CHIKV viral RNA. Four-week-old WT C57BL/6 male mice were inoculated with 103 FFU of CHIKV-LR. At 2 dpi,
400 g of agonistic anti-CD137 MAb or isotype-control MAb was administered via the i.p. route. (A) Spleens were harvested at 7 dpi, and viral RNA (brown) was
visualized by ISH. Tissue sections were counterstained with Gill’s hematoxylin. Scale bars, 50 m. (B) Insets of panel A (black boxes) visualized at higher
magniﬁcation. Scale bars, 10 m. Yellow arrows indicate CHIKV RNA. (C) Spleens were harvested at 7 dpi (left) or 14 dpi (right), and bulk cells were ﬁxed with
PFA and sorted using ﬂow cytometry. Viral RNA in each sorted cell subset was measured by qRT-PCR and normalized to 18S. (D to F) Four-week-old WT C57BL/6
male mice were inoculated with 103 PFU of CHIKV SL15649. Spleens were harvested at 3, 7, and 14 dpi, CHIKV E1 (D) and nsP2 (E) RNA from tissue homogenates
was measured by qRT-PCR, and the ratio of E1 RNA to nsP2 RNA was calculated (F). Data were pooled from two experiments. Each symbol represents one mouse,
and bars indicate median values. *, P ⬍ 0.05; **, P ⬍ 0.01; ***, P ⬍ 0.001; ****, P ⬍ 0.0001, Mann-Whitney test.

antiviral antibody responses, we measured anti-CHIKV IgG levels in the serum of
infected mice at 30 dpi. Consistent with the reduced numbers of germinal center B
cells, we observed lower (32-fold; P ⬍ 0.001) levels of anti-CHIKV IgG in anti-CD137
MAb-treated animals than in isotype-control MAb-treated animals (Fig. 3H).
December 2019 Volume 93 Issue 24 e01231-19
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B cells are required for persistence of CHIKV RNA in the spleen. Since splenic
germinal center B cells and FDCs showed the greatest quantities of viral RNA, on a
per-cell basis, after CHIKV infection, we further evaluated the contributions of these
cells to the persistence of CHIKV RNA in the spleen. Initially, at 2 dpi we treated
isotype-control MAb-treated mice with an anti-CD40L-blocking MAb, which inhibits the
engagement of CD40L on B cells with its receptor CD40 on T helper cells and results in
impaired germinal center formation (21). As expected, administration of CD40Lblocking MAb reduced the numbers of germinal center B cells and FDCs at 14 dpi, by
108- and 7-fold, respectively (Fig. 4A to D). This depletion was associated with an
⬃5-fold reduction in CHIKV RNA levels in the spleen, although the difference did not
attain statistical signiﬁcance (Fig. 4E, black circles). In comparison, treatment with
anti-CD137 MAb in combination with CD40L-blocking MAb or the block-isotype-control
MAb reduced viral RNA levels in the spleen, compared with treatment with isotypecontrol MAb in combination with CD40L-blocking MAb (123-fold; P ⬍ 0.05) or blockisotype-control MAb (660-fold; P ⬍ 0.001), respectively (Fig. 4E, black and red circles on
the left or right, respectively). Collectively, these experiments show that, although
germinal center B cells and FDCs in the spleens of isotype-control MAb-treated mice
contain high levels of CHIKV RNA, other cell populations contribute to the persistence
of CHIKV RNA.
Based on these data, we speculated that non-germinal center B cells also harbored
CHIKV RNA in the spleen. Indeed, when we depleted all CD20⫹ B cells using an
anti-CD20 MAb at 2 dpi, we observed a 75-fold reduction (P ⬍ 0.001) in CHIKV RNA in
the spleen at 14 dpi (Fig. 4F and G, black circles). To corroborate these data, B6.129S2December 2019 Volume 93 Issue 24 e01231-19
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FIG 3 Anti-CD137 MAb treatment reduces the number of germinal center B cells and FDCs. Four-week-old WT C57BL/6 male mice were inoculated with 103
FFU of CHIKV-LR. At 2 dpi, 400 g of agonistic anti-CD137 MAb or isotype-control MAb was administered via the i.p. route. (A to G) The numbers of total CD45⫹
leukocytes (A), CD3⫹ T cells (B), CD19⫹ B cells (C), PNA⫹ CD95⫹ or GL7⫹ CD95⫹ germinal center B cells (D and E), and CD45⫺ CD54⫹ CD21/CD35⫹ FDCs (F and
G) in the spleen at 14 dpi were analyzed by ﬂow cytometry. Representative ﬂow cytometry dot plots of germinal center B cells (D) and FDCs (F) are shown. The
numbers within the ﬂow cytometry plots refer to the percentage of cells in the gated (boxed or circled) areas. (H) Serum was harvested at 30 dpi, and anti-CHIKV
IgG titers were measured by ELISA. Each symbol represents an individual mouse, and bars indicate median values (with the exception of panel H, where mean
values were used). Data were pooled from two or three experiments. *, P ⬍ 0.05; **, P ⬍ 0.01; ***, P ⬍ 0.001; ****, P ⬍ 0.0001; n.s., not signiﬁcant, Mann-Whitney
test.

Journal of Virology

FIG 4 B cells are required for the persistence of CHIKV RNA in the spleen. (A to G) Four-week-old WT C57BL/6 male mice were inoculated with 103 FFU of
CHIKV-LR. At 2 dpi, 400 g of agonistic anti-CD137 MAb or isotype-control MAb in combination with CD40L-blocking MAb or block-isotype-control MAb (A to
E) or anti-CD20 depleting MAb or depletion-isotype-control MAb (F and G) was administered via the i.p. route. Spleens were harvested at 14 dpi, and the
numbers of PNA⫹ CD95⫹ germinal center B cells (A and B) and CD45⫺ CD54⫹ CD21/CD35⫹ FDCs (C and D) were determined by ﬂow cytometry. Representative
ﬂow cytometry dot plots of germinal center B cells (A), FDCs (C), and CD19⫹ B cells (F) are shown. Viral RNA from tissue homogenates was measured by qRT-PCR
(E and G). (H to J) Four-week-old MT mice (H) or MD4 transgenic mice with a MT background (I and J) were inoculated with 103 FFU of CHIKV-LR. For MT
mice (H), 400 g of agonistic anti-CD137 MAb or isotype-control MAb was administered at 2 dpi. Spleens were harvested at 7 or 14 dpi, and viral RNA was
measured. In panels H and J, each symbol represents an individual mouse, and bars indicate median values. *, P ⬍ 0.05; **, P ⬍ 0.01; ***, P ⬍ 0.001; ****,
P ⬍ 0.0001; n.s., not signiﬁcant, Kruskal-Wallis ANOVA with Dunn’s posttest. At 14 dpi, the spleen was removed and processed for ﬂow cytometry (I). Splenocytes
were gated as B220⫹ CD19⫹ for B cells. Representative ﬂow plots for each genotype are shown. WT B cells are IgMb⫹, and HEL-speciﬁc (MD4) B cells are IgMa⫹.
MD4 B cells were also conﬁrmed by staining with HEL (data not shown). Data were pooled from two to four experiments. In this ﬁgure, the numbers within
the ﬂow cytometry plots refer to the percentage of cells in the adjacent gated (boxed or circled) areas.

Ighmtm1Cgn/J (MT) (B cell-deﬁcient) mice were inoculated with CHIKV and treated with
anti-CD137 MAb at 2 dpi. Viral RNA levels at 7 dpi in the spleens of MT mice were
lower than those in WT mice with anti-CD137 MAb treatment (87-fold; P ⬍ 0.001) or
without it (299-fold; P ⬍ 0.001) (Fig. 1F and Fig. 4H). However, the levels of viral RNA in
the spleens of anti-CD137 MAb-treated and isotype-control MAb-treated MT mice at
7 dpi were similar. At 14 dpi, almost no CHIKV RNA was detected in the spleens of these
mice with or without anti-CD137 MAb treatment (Fig. 4H).
Antigen in the form of immune complexes can be captured by cells expressing Fc␥
or complement receptors (CRs), or antigen can be directly captured by B cell receptors.
We next tested whether CHIKV-speciﬁc antibody was required for the persistence of
viral RNA in the spleen. To assess this, we used transgenic MD4 mice in a MT
December 2019 Volume 93 Issue 24 e01231-19
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background; these mice have B cell receptors that are speciﬁc for only hen egg
lysozyme (HEL) (Fig. 4I) (22). At 14 dpi, viral RNA was detected in the spleens of MD4
mice, albeit at substantially lower levels than in WT mice, whereas almost no viral RNA
was measured in the spleens of MT mice (Fig. 4J). Thus, the antigen speciﬁcity of B
cells contributes to the persistence of CHIKV RNA in the mouse spleen.
T cells are required for anti-CD137-mediated clearance of CHIKV in the spleen.
We hypothesized that the agonistic anti-CD137 MAb cleared CHIKV RNA in lymphoid
tissues by activating CD137⫹ immune cells with effector activity (1). By ﬂow cytometry,
we detected CD137 expression on splenic CD4⫹ and CD8⫹ T cells, NK cells, and natural
killer T (NKT) cells in CHIKV-infected mice at 2 dpi (Fig. 5). To deﬁne the cells responsible
for anti-CD137 MAb-mediated clearance of CHIKV RNA, we performed anti-CD137 MAb
treatment experiments in mice depleted of NK cells, CD8⫹ T cells, CD4⫹ T cells, or
neutrophils. Administration of anti-CD137 MAb in NK cell-, CD8⫹ T cell-, or CD4⫹ T
cell-depleted mice resulted in diminished CHIKV RNA levels in the spleen at 14 dpi,
although the reductions were only 2- to 5-fold lower than with control nondepleting
MAbs (Fig. 6A to F). Ab-mediated depletion of both CD4⫹ and CD8⫹ T cells resulted in
9-fold less clearance effect of anti-CD137 MAb (Fig. 6G and H). Similarly, Ab-mediated
triple depletion of CD4⫹ and CD8⫹ T cells and NK cells resulted in 21-fold less clearance
by anti-CD137 MAb (Fig. 6I and J). In comparison, depletion of neutrophils did not affect
anti-CD137 MAb-mediated clearance of CHIKV RNA in the spleen at 14 dpi (Fig. 6K and
L). Consistent with a dominant role for CD3⫹ cells in mediating clearance of CHIKV RNA
in the spleen, the effect of anti-CD137 MAb was abolished completely in B6.129P2Tcrbtm1Mom Tcrdtm1Mom/J (TCR␤␦⫺/⫺) mice, which lack all T cell and NKT cell subsets
(Fig. 6M).
Anti-CD137 MAb treatment reduces MAYV RNA levels. We assessed the effect of
anti-CD137 MAb on a second alphavirus, MAYV, to determine whether the clearance
phenotype was speciﬁc to CHIKV. In contrast to ﬁndings observed with CHIKV-infected
mice, treatment with anti-CD137 MAb reduced (8-fold; P ⬍ 0.0001) viral RNA levels in
the ipsilateral foot of MAYV-infected mice at 14 dpi (Fig. 7A), although viral RNA levels
in the contralateral foot of anti-CD137 MAb-treated and isotype-control MAb-treated
mice were similar (Fig. 7B). Similar to CHIKV-infected mice, anti-CD137 MAb treatment
resulted in markedly reduced MAYV RNA levels in the spleen (241-fold; P ⬍ 0.0001) and
DLN (5,962-fold; P ⬍ 0.001) at 14 dpi (Fig. 7C and D). Thus, anti-CD137 MAb-mediated
clearance of viral RNA in lymphoid tissues occurred in the context of multiple alphavirus
infections in mice, whereas reduction of viral RNA in musculoskeletal tissues was virus
type speciﬁc.
DISCUSSION
In this study, we observed that agonistic anti-CD137 MAb administered at 2 dpi
cleared CHIKV RNA in the spleen and DLN by 28 dpi, although viral RNA in musculoskeletal tissues of the foot persisted. In a parallel model of infection with MAYV, another
arthritogenic alphavirus, anti-CD137 MAb treatment also reduced MAYV RNA levels in
the spleen and DLN by 14 dpi. In the MAYV model, however, a partial clearance effect
was observed in the ipsilateral foot but not the contralateral foot. Based on our
cell-sorting and tropism data, germinal center B cells and FDCs were associated with
the highest levels of viral RNA in the spleen, on a per-cell basis, at 7 and 14 dpi. Flow
cytometric analysis revealed that anti-CD137 MAb treatment reduced the numbers of
germinal center B cells and FDCs, and this was associated with diminished anti-CHIKV
IgG responses. Inhibition of germinal center formation by anti-CD137 MAb also was
observed in mice immunized with sheep red blood cells or keyhole limpet hemocyanin
(23). When B cells were depleted using anti-CD20 MAb, CHIKV RNA levels in the spleen
also were reduced at 14 dpi. Together, these data suggest a key role for B cells in
maintaining persistent CHIKV RNA in the spleen. Consistent with these results, MT
mice lacking B cells had almost no detectable viral RNA in the spleen at 14 dpi, and
MD4 transgenic mice, which have B cells speciﬁc for HEL, also had less CHIKV RNA in the
spleen at 14 dpi. These data suggest that antigen-speciﬁc B cells are responsible for the
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FIG 5 CD137 is expressed on splenic CD4⫹ and CD8⫹ T cells, NK cells, and NKT cells in CHIKV-infected
mice at 2 dpi. Four-week-old WT C57BL/6 mice were inoculated with 103 FFU of CHIKV-LR at day 0. At
2 dpi, spleens were harvested and processed for ﬂow cytometry. Flow cytometry dot plots show CD137
expression levels on CD4⫹ and CD8⫹ T cells, CD3-NK1.1⫹ NK cells, CD19⫹ B cells, MHC-II⫹ CD11c⫹ DCs,
and CD3⫹ NK1.1⫹ NKT cells. Data are representative of two experiments. The numbers within the ﬂow
cytometry plots refer to the percentage of cells in the gated (boxed) areas.
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FIG 6 Anti-CD137 MAb-mediated clearance of CHIKV RNA in the spleen is abolished in mice lacking T cells. Four-week-old WT (A to L) or TCR␤␦⫺/⫺ C57BL/6
(M) mice were inoculated with 103 FFU of CHIKV-LR. At 2 dpi, 400 g of agonistic anti-CD137 MAb or isotype-control MAb in combination with anti-NK1.1
depleting MAb or depletion-isotype-control MAb (A and B), anti-CD8␣ depleting MAb or depletion-isotype-control MAb (C and D), anti-CD4 depleting MAb or
depletion-isotype-control MAb (E and F), anti-CD8␣ and anti-CD4 depleting MAbs or depletion-isotype-control MAbs (G and H), anti-CD8␣, anti-CD4, and
anti-NK1.1 depleting MAbs or depletion-isotype-control MAbs (I and J), or anti-Ly6G depleting or depletion-isotype-control MAb (K and L) was administered
via the i.p. route. All depleting and depletion-isotype-control MAbs were administered every 4 days, except for anti-Ly6G and isotype-control MAbs, which were
administered every 2 days. Spleens were harvested at 14 dpi, and viral RNA from tissue homogenates was measured by qRT-PCR. Data were pooled from two
or three experiments. Each symbol represents an individual mouse, and bars indicate median values. *, P ⬍ 0.05; ***, P ⬍ 0.001; ****, P ⬍ 0.0001; n.s., not
signiﬁcant, Mann-Whitney test. Representative ﬂow cytometry dot plots conﬁrming cell depletions are shown (A, C, E, G, I, and K). The numbers within the ﬂow
cytometry plots refer to the percentage of cells in the gated (boxed or circled) areas.

persistence of CHIKV RNA in mouse spleen. Anti-CD137 MAb-mediated clearance of
CHIKV RNA in the spleen was diminished in anti-NK1.1-, anti-CD4-, and anti-CD8-treated
mice and was abrogated in TCR␤␦⫺/⫺ mice, which lack CD4⫹ and CD8⫹ T cells, NKT
cells, and ␥␦ T cells in the spleen. Thus, anti-CD137 MAb-mediated clearance of CHIKV
in lymphoid tissues is dependent primarily on T cells.
The basis of CHIKV RNA persistence in musculoskeletal tissues of infected animals
remains a longstanding question in the ﬁeld. Although anti-CD137 MAb treatment had
marked effects in lymphoid tissues, it did not signiﬁcantly alter CHIKV RNA levels in the
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ipsilateral foot or the contralateral foot at 7, 14, or 28 dpi. The lack of CHIKV RNA
clearance in the musculoskeletal tissues after anti-CD137 MAb treatment may be due
to the distinct viral tropism in these tissues. During the acute phase of infection, CHIKV
is readily detected in skeletal muscle cells, synovial ﬁbroblasts, and other nonhematopoietic cells in mice (24, 25). During the chronic phase, the reservoir of CHIKV in muscle
and joint tissues is less clear, although experiments with a Cre recombinase CHIKV
strain and reporter mice showed that ﬁbroblasts and skeletal muscle cells harbored
persistent viral RNA (25). In contrast to our observations in the CHIKV model, agonistic
anti-CD137 MAb treatment reduced viral RNA levels in the ipsilateral foot in the MAYV
model. Although further study is warranted, the cellular tropism of MAYV may differ
from that of CHIKV, as has been reported for other arthritogenic alphaviruses, such that
additional infected cell types can be cleared by anti-CD137-activated T cells (26).
Our experiments showed that, in the spleen, germinal center B cells and FDCs were
associated with high levels of CHIKV RNA at 7 and 14 dpi. Although viral RNA was
readily detected, we did not recover infectious CHIKV from lymphoid tissues at those
time points, as judged by plaque- or focus-forming assays. Notwithstanding these data,
we observed higher E1/nsP2 RNA ratios, consistent with productive CHIKV infection.
Additionally, B cells may capture CHIKV immune complexes via surface CRs and Fc␥
receptors and transport it to FDCs in the B cell follicles (27, 28). Marginal zone B cells
continuously shuttle between marginal zone and follicular areas, which can facilitate
antigen transport (28). Alternatively, immune complexes taken up by subcapsular sinus
or marginal zone macrophages can be transferred to CR2-expressing B cells, which then
transport the immune complexes to CR2-expressing FDCs (29).
FDCs are thought to retain opsonized antigen for extended periods and present it
to cognate B cells to form germinal centers (30). As an example, human FDCs isolated
from patients retain HIV within nondegradative cycling compartments for long periods
(31). Clearance of CHIKV RNA in the spleen after anti-CD137 MAb treatment correlated
with reductions in the number of germinal center B cells and FDCs. Moreover, the levels
of viral RNA in the spleen were reduced in MT or MD4 transgenic mice lacking
CHIKV-speciﬁc B cells and Abs. Based on our tropism analysis, blocking studies with
anti-CD40L MAb, depletion studies with anti-CD20 MAb, and infection experiments in
MT B cell-deﬁcient mice, it appears that multiple subtypes of B cells and FDCs retain
much of the CHIKV RNA in lymphoid tissues during the subacute and chronic phases of
infection.
Antitumor mechanisms of anti-CD137 MAb activity are thought to depend on direct
killing by CD8⫹ T cells and NK cells, enhanced proliferation and cytokine secretion by
tumor-speciﬁc T cells, and Ab-dependent cell-mediated cytotoxicity of NK cells at tumor
sites (1). In a mouse B cell lymphoma model, depletion of CD8⫹ T cells or NK cells
abrogated the antitumor effect of anti-CD137 MAb (32). Although the antitumor effect
of anti-CD137 MAb is mediated through engagement of CD8⫹ T cells in most preclinical
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FIG 7 Anti-CD137 MAb treatment reduces levels of MAYV RNA in the spleen, DLN, and ipsilateral foot. Four-week-old WT C57BL/6 male mice were inoculated
with 103 FFU of MAYV BeH407. At 2 dpi, 400 g of agonistic anti-CD137 MAb or isotype-control MAb was administered via the i.p. route. Ipsilateral (A) and
contralateral (B) feet, spleen (C), and DLN (D) were harvested at 14 dpi. Viral RNA from tissue homogenates was measured by qRT-PCR. Each symbol represents
an individual mouse, and bars indicate median values. Data were pooled from three experiments. ***, P ⬍ 0.001; ****, P ⬍ 0.0001; n.s., not signiﬁcant,
Mann-Whitney test.
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tumor models, the role of CD4⫹ T cells is less clear. Depletion of CD4⫹ T cells improved
the therapeutic efﬁcacy of anti-CD137 MAb in a mouse B cell lymphoma model (32),
whereas CD4⫹ T cells were required for anti-CD137 MAb-induced antitumor immunity
in a mouse mastocytoma model (33). Based on our cell depletion experiments, antiCD137 MAb-mediated clearance of persistent CHIKV RNA was only partially dependent
on NK cells and CD4⫹ and CD8⫹ T cells. However, anti-CD137 MAb-mediated clearance
of CHIKV RNA was abrogated in TCR␤␦⫺/⫺ mice. Immune cell subsets other than
conventional CD4⫹ or CD8⫹ T cells, such as NKT cells, that are absent in these mice
could contribute to anti-CD137 MAb-mediated clearance of CHIKV RNA in the spleen.
Because B cells are a major reservoir of persistent CHIKV RNA in the spleen, we
hypothesize that anti-CD137 MAb clears persistent CHIKV RNA in the spleen and DLN
by targeting B cells. Further study is necessary to deﬁne how activation by anti-CD137
MAb induces T cells and possibly NKT cells to lyse and/or to prevent expansion of B cells
and to determine whether any of this process is antigen speciﬁc.
Our study helps to elucidate the basis for retention of CHIKV RNA in secondary
lymphoid tissues. The clearance of CHIKV RNA coincided with a reduction in B cells and
FDCs that was mediated by anti-CD137 MAb treatment and T cells. These effects on
germinal center formation may be relevant for infections and vaccinations that occur in
patients treated with agonistic anti-CD137 MAb therapies for cancers. Although further
study is warranted, treatment with anti-CD137 MAbs might blunt the humoral response
to newly administered vaccines or infection with pathogens.

Viruses and cells. A recombinant CHIKV La Reunion (CHIKV-LR) OPY1 strain was provided by S. Higgs
(Kansas State University) and generated from in vitro-transcribed cDNA as described (34). The resultant
virus was propagated once in C6/36 Aedes albopictus cells and titrated using Vero cells, as described (35).
CHIKV SL15649 was generated in BHK21 cells from in vitro-transcribed cDNA, as described (36). The MAYV
BeH407 strain was provided by the World Reference Center for Arboviruses (S. Weaver, K. Plante, and R.
Tesh) and propagated in Vero cells.
Animal studies. All animal experiments were performed with the approval of Washington University
and University of Colorado School of Medicine institutional animal care and use committees, in
accordance with their guidelines. C57BL/6J (product no. 000664), B6.129S2-Ighmtm1Cgn/J (MT) (product
no. 002288), and B6.129P2-Tcrbtm1Mom Tcrdtm1Mom/J (TCR␤␦⫺/⫺) (product no. 002121) mice were purchased from the Jackson Laboratory. CD137⫺/⫺ mice (37) were obtained as a gift from Michael Croft (La
Jolla Institute for Immunology). MD4 mice (22) with a MT B cell-deﬁcient genetic background were
generated at the University of Colorado, by crossing mice with the MD4 transgene (product no. 002595;
The Jackson Laboratory) with mice of the MT B cell-deﬁcient background. At 4 weeks of age, male mice
anesthetized with ketamine hydrochloride (80 mg/kg body weight) and xylazine (15 mg/kg) were
inoculated subcutaneously, in the left rear footpad, with 103 focus-forming units (FFU) of CHIKV or MAYV
in 10 l of phosphate-buffered saline (PBS). Foot swelling was measured daily with digital calipers
(product no. 54-100-004-2; Fowler). At the termination of experiments, mice were euthanized and
perfused with PBS via intracardiac injection. Tissues were harvested and stored at – 80°C.
Quantitative reverse transcription-PCR. Viral RNA was extracted from tissue homogenates using
the RNeasy minikit (product no. 74182; Qiagen). To extract viral RNA from PFA-ﬁxed cells, the RNeasy kit
for puriﬁcation of total RNA from formalin-ﬁxed, parafﬁn-embedded tissue sections (product no. 73504;
Qiagen) was used, according to the manufacturer’s protocol. qRT-PCR was performed using the TaqMan
RNA-to-CT 1-step kit (Applied Biosystems) with a CHIKV E1- or MAYV E2-speciﬁc primer/probe set (38, 39).
The extracted RNA was compared to a standard curve generated with RNA extracted from a CHIKV or
MAYV stock, to determine FFU equivalents. To quantify CHIKV genomic and subgenomic RNA levels in
the spleen, random primed cDNA was used as a template for CHIKV-sequence-speciﬁc forward
(CHIKV2444, 5=-TTTGCGTGCCACTCTGG-3=) and reverse (CHIKV2524, 5=-CGGGTCACCACAAAGTACAA-3=)
primers and a CHIKV-sequence-speciﬁc TaqMan probe (CHIKV2467, 5=-6-carboxyﬂuorescein [FAM]-ACTT
GCTTTGATCGCCTTGGTGAGA-3=) that ampliﬁed a region of the nsP2 gene. The same random primed
cDNA was also used as a template for CHIKV-sequence-speciﬁc forward (CHIKV10239, 5=-CGGCGTCTAC
CCATTTATGT-3=) and reverse (CHIKV10363, 5=-CCCTGTATGCTGATGCAAATTC-3=) primers and a CHIKVsequence-speciﬁc TaqMan probe (CHIKV10290, 5=-FAM-AAACACGCAGTTGAGCGAAGCAC-minor groove
binder [MGB]-3=) that ampliﬁed a region of the E1 gene. A standard curve composed of 10-fold dilutions
(from 107 to 100 copies) of CHIKV positive-strand genomic RNA, synthesized in vitro and spiked into RNA
from BHK21 cells, was used to determine the nsP1 and E1 gene copy numbers and to conﬁrm that the
two assays ampliﬁed with similar efﬁciencies. To determine the relative abundance of the subgenomic
RNA, compared with full-length genomic RNA, the data were expressed as a ratio of the E1 gene copy
number to the nsP2 gene copy number.
Antibodies and cell depletions. Anti-CD137 MAb (clone 2A, rat Ig2a MAb) has been described
previously (40). Antibody was puriﬁed from hybridoma supernatants by protein G afﬁnity chromatography, by a commercial vendor (Bio X Cell). Anti-CD4 (clone GK1.5), anti-CD8 (clone YTS169.4), anti-NK1.1
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(clone PK136), anti-Ly6G (clone 1A8), anti-CD40L (clone MR-1), rat IgG2b isotype control (clone LTF-2) for
CD4⫹ and CD8⫹ T cell depletion, mouse IgG2a (clone C1.18.4) for NK and B cell depletion, rat IgG2a
isotype control (clone 2A3) for neutrophil depletion, and polyclonal Armenian hamster IgG for CD40L
blockade were purchased from Bio X Cell. Anti-CD20 (clone 5D2) was obtained from Genentech. Mice
were administered 400 g of anti-CD137 MAb or rat Ig2a isotype-control MAb (clone 2A3; Bio X Cell), via
the intraperitoneal (i.p.) route, at 2 dpi. For cell depletion studies, mice were administered 300 g of
anti-CD4 MAb, 500 g of anti-CD8 MAb, or 200 g of anti-NK1.1 MAb at 2 dpi and every 4 days thereafter
until 14 dpi or 500 g of anti-Ly6G antibody at 2 dpi and every 2 days thereafter until 14 dpi. For B cell
depletion, mice were administered 200 g of anti-CD20 MAb at 2 dpi. For CD40L blocking, mice were
administered 500 g of anti-CD40L MAb at 2 dpi and every 3 days thereafter until 14 dpi.
RNA ISH. Uninfected and infected mice were sacriﬁced and perfused extensively with PBS via
intracardiac injection. The spleen was dissected, ﬁxed with 1% PFA in PBS for 2 h at room temperature,
and transferred to 10% sucrose in PBS at 4°C. After overnight incubation, tissues were placed overnight
in 30% sucrose in PBS at 4°C and then frozen in Tissue-Tek compound (product no. 4583; Sakura) at
– 80°C. Tissues were cut in 10-m sections. Viral RNA ISH was performed using RNAscope 2.5 (Advanced
Cell Diagnostics), according to the manufacturer’s instructions. The probe targeting CHIKV RNA was
designed and synthesized by Advanced Cell Diagnostics (product no. 479501). All samples were
visualized using a Nikon Eclipse microscope with a QICAM 12-bit camera (QImaging), and results were
processed with QCapture software.
Immune cell analysis. Ipsilateral feet from CHIKV-infected mice were skinned and incubated for 2 h
at 37°C in 10 ml of digestion buffer (2.5 mg/ml collagenase [Sigma] and 10 g/ml DNase I [Sigma] in RPMI
1640 medium containing 10% fetal bovine serum [FBS]). The cell suspension was passed through a
70-m cell strainer. After centrifugation, cells were washed with 1% FBS in Hanks’ balanced salt solution,
followed by another round of centrifugation and washing. Cells were resuspended in washing buffer (5%
FBS in PBS) at 5 ⫻ 106 cells/ml and incubated with 2.5 g of anti-mouse CD16/CD32 antibody (product
no. 101302; BioLegend) per 106 cells for 20 min on ice. Cells were then stained with Brilliant violet 605
(BV605)-conjugated anti-CD45 (product no. 103140; BioLegend), ﬂuorescein isothiocyanate (FITC)conjugated anti-CD3 (product no. 11-0031-85; Invitrogen), phycoerythrin (PE)-conjugated anti-CD4
(product no. 553049; BD Biosciences), peridinin-chlorophyll-protein (PerCP)/Cy5.5-conjugated anti-CD8␣
(product no. 100734; BioLegend), PE/cyanine 7 (Cy7)-conjugated anti-NK1.1 (product no. 108714; BioLegend), allophycocyanin (APC)/Cy7-conjugated anti-CD19 (product no. 115530; BioLegend), BV421conjugated anti-Ly6C (product no. 562727; BD Biosciences), or Alexa Fluor 700-conjugated anti-Ly6G
(product no. 127622; BioLegend) antibody. Subsequently, cells were ﬁxed and permeabilized with the
eBioscience FoxP3/transcription factor staining kit and incubated with Alexa Fluor 647-conjugated
anti-FoxP3 antibody (product no. 126408; BioLegend).
Spleens from CHIKV-infected mice were minced and incubated for 30 min at 37°C in 2 ml digestion
buffer (1 mg/ml collagenase [Sigma] and 100 g/ml DNase I [Sigma] in Dulbecco’s modiﬁed Eagle’s
medium [DMEM] containing 2% FBS), in a 24-well plate. The cell suspension was passed through a
100-m cell strainer. After rinsing with 10% FBS, 5 mM EDTA, in DMEM, erythrocytes were lysed for 2 min
with 1 ml of ammonium-chloride-potassium (ACK) lysing buffer (Gibco). Cells were washed with DMEM
and centrifuged, followed by rinsing with washing buffer (2% FBS, 5 mM EDTA, in PBS). After centrifugation, cells were resuspended in washing buffer at 5 ⫻ 108 cells/ml and were incubated for 20 min with
2.5 g of anti-mouse CD16/CD32 antibody (product no. 101302; BioLegend) per 108 cells, on ice. Then,
cells were stained with BV605-conjugated anti-CD45 (product no. 103140; BioLegend), PE/Cy7conjugated anti-CD3 (product no. 100320; BioLegend), APC/Cy7-conjugated anti-CD19 (product no.
115530; BioLegend), PerCP/Cy5.5-conjugated anti-CD11c (product no. 117328; BioLegend), FITCconjugated anti-CD21/CD35 (product no. 553818; BD Biosciences), BV421-conjugated anti-CD54 (product
no. 564704; BD Biosciences), or PE-conjugated anti-CD95 (product no. 554258; BD Biosciences) antibody
and biotin-conjugated PNA (product no. B-1075; Vector Laboratories). To conﬁrm CD137 expression, cells
were stained with biotin-conjugated anti-CD137 (product no. 106104; BioLegend). Cells were then
washed and incubated with Alexa Fluor 647-conjugated streptavidin (product no. S32357; Invitrogen).
Subsequently, cells were ﬁxed with BD FACS lysing solution, processed on an LSR Fortessa X-20 (BD
Biosciences) ﬂow cytometer, and analyzed using BD FACSDiva and FlowJo software. For ﬂuorescenceactivated cell sorting, a BD FACSAria II system was used.
Serum anti-CHIKV IgG ELISA. MaxiSorp 96-well ﬂat-bottomed enzyme-linked immunosorbent assay
(ELISA) plates (Thermo Fisher) were coated overnight at 4°C with 2 g/ml of CHIKV E2 protein (35). Plates
were washed with ELISA wash buffer (PBS with 0.05% Tween 20) and blocked with blocking buffer (PBS
with 5% FBS) for 4 h at 37°C. Sera from CHIKV-infected mice were added in 3-fold dilutions starting with
a 1:100 dilution. After incubation for 1 h at room temperature, plates were washed with ELISA wash
buffer. Plates were incubated with biotinylated anti-IgG (product no. 115-065-062; Jackson ImmunoResearch) for 1 h at room temperature. After washing, plates were incubated with streptavidin-conjugated
horseradish peroxidase (product no. SA-5004; Vector Laboratories) for 30 min at room temperature. After
sequential washes with ELISA buffer and PBS, substrate solution (Thermo Fisher) was added. The reaction
was quenched with 2 N H2SO4. The plates were read using a Synergy H1 hybrid reader (BioTek). The
optical density (OD) (450 nm) value of naive serum was subtracted from the OD values of CHIKV-infected
samples, and nonlinear regression curves were calculated. Anti-CHIKV IgG titers were deﬁned as the
dilution of serum yielding a half-maximal OD value after background and naive value subtraction.
Statistical analysis. All data were analyzed with GraphPad Prism software. For viral RNA analysis and
immune cell analysis, data were analyzed by the Mann-Whitney test, Kruskal-Wallis analysis of variance
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(ANOVA) with Dunn’s posttest, or two-way ANOVA with Šidák’s posttest. P values of ⬍0.05 indicate
statistically signiﬁcant differences.
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